Monitor the July 31, 2026 shareholder vote for signals of support; watch for definitive agreement execution and confirmatory due diligence results. The non-binding nature means deal could still fail — track any competing bids during the 30-day exclusivity period. If approved, the combined company's success hinges on Infinite's ability to commercialize its epigenetic diagnostics platform and achieve reimbursement.
Price Chart
Executive Summary
Nano Dimension announced a non-binding term sheet to merge with Infinite Epigenetics, an AI-powered preventive health and diagnostics company, in a stock-for-stock deal valuing Infinite at $890 million. Existing Nano shareholders would retain a meaningful minority stake in the combined company (to be renamed Infinite Epigenetics, ticker IEAI) based on a 20% premium to Nano's estimated net cash at closing, with the combined entity expected to have over $400 million in cash. The deal is transformative but non-binding, subject to definitive agreement, due diligence, shareholder votes, and regulatory approvals, with a key shareholder vote on July 31, 2026, to authorize continuation of the strategic process.
Key Financial Metrics
Key Facts
- Nano Dimension entered a non-binding term sheet to acquire Infinite Epigenetics in a stock-for-stock merger valuing Infinite at $890 million.
- Existing Nano shareholders expected to retain meaningful minority ownership based on a 20% premium to Nano's estimated net cash at closing.
- Combined company to operate as Infinite Epigenetics on Nasdaq under ticker IEAI, with over $400 million in cash at closing.
- Infinite Epigenetics has collected 120,000+ epigenetic samples since 2020 and targets a $90B+ U.S. clinical diagnostics market.
- Transaction subject to definitive agreement, confirmatory due diligence, Nano shareholder approval, regulatory approvals, and Nano re-domestication to the U.S.
- Break fee of $10 million (2.5% of Nano Equity Valuation) payable by Nano in certain termination scenarios, with escrow required.
- Shareholder vote on July 31, 2026, is a non-binding advisory vote to continue the strategic alternatives process, not a final vote on the transaction.
Financial Impact
Infinite Epigenetics valued at $890 million; combined company expected to have over $400 million cash at closing; Nano shareholders receive 20% premium to net cash plus contingent value rights for legacy asset proceeds.
Risk Factors
- Non-binding term sheet — no guarantee of definitive agreement or closing.
- Significant dilution for existing Nano shareholders who become minority owners.
- Execution risk: Infinite Epigenetics is pre-revenue at scale and faces regulatory, reimbursement, and competitive hurdles.
- Shareholder approval risk — the July 31 vote is advisory but signals sentiment.
- Regulatory approvals required, including Israeli law and Nasdaq listing for combined entity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001104659-26-073777 |
| Document: tm2617934d1_ex99-2.htm | 0001104659-26-073777 |
| Document: tm2617934d1_8k.htm | 0001104659-26-073777 |
| Document: tm2617934d1_ex99-3.htm | 0001104659-26-073777 |
| Document: tm2617934d1_ex99-1.htm | 0001104659-26-073777 |
| Document: 0001104659-26-073777-index-headers.html | 0001104659-26-073777 |
| Document: 0001104659-26-073777-index.html | 0001104659-26-073777 |
| Document: 0001104659-26-073777.txt | 0001104659-26-073777 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | 3 | $1.59 $1.58 | ▼ −0.63% | ▼ −0.85% | $1.62 (+1.89%) |
Aug 18, 2026 6w ago | 8-K | $1.55 $1.54 | ▼ −0.65% | ▲ +0.34% | $1.62 (+4.52%) |
Jul 21, 2026 10w ago | 8-K | $1.48 $1.53 | ▲ +3.38% | ▲ +0.48% | $1.62 (+9.46%) |
Jul 14, 2026 11w ago | 144 | $1.50 $1.66 | ▲ +10.67% | ▲ +8.18% | $1.62 (+8.00%) |
Jul 10, 2026 12w ago | DEFA14A | $1.50 $1.63 | ▼ −8.67% | ▼ −6.24% | $1.62 (−8.00%) |
Jun 29, 2026 13w ago | DEFA14A | $1.45 $1.48 | ▲ +2.07% | ▲ +3.10% | $1.62 (+11.72%) |
Jun 16, 2026 15w ago | Press Release | $1.34 $1.48 | ▲ +10.45% | ▲ +9.13% | $1.62 (+20.90%) |
Jun 15, 2026 15w ago | 425 | $1.25 $1.48 | ▲ +18.40% | ▲ +19.15% | $1.62 (+29.60%) |
Jun 15, 2026 15w ago | 8-K | $1.25 $1.48 | ▲ +18.40% | ▲ +19.15% | $1.62 (+29.60%) |
Jun 15, 2026 15w ago | Press Release | $1.25 $1.48 | ▲ +18.40% | ▲ +19.15% | $1.62 (+29.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access